Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06072781 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Study acronym: RAMP 301
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 99 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 1 of 11 entries Site details revised at 5 of 106 sites Show 1 more changeShow less
    • Site details revised at 5 of 106 sites
  2. Site details revised at 1 of 106 sitesv98
  3. Site contacts updated at 2 of 106 sitesv97
  4. Site details revised at 1 of 106 sitesv96
  5. Site contacts updated at 1 of 106 sitesv95
Show 45 earlier versionsHide 45 earlier versions
  1. Site contacts updated at 1 of 106 sitesv94
  2. Site contacts updated at 1 of 106 sitesv93
  3. Site contacts updated at 1 of 106 sitesv92
  4. Site contacts updated at 1 of 106 sitesv91
  5. Site contacts updated at 2 of 106 sitesv90
  6. Site contacts updated at 2 of 106 sitesv89
  7. Site contacts updated at 1 of 106 sitesv88
  8. Site contacts updated at 1 of 106 sitesv87
  9. Site contacts updated at 1 of 106 sitesv86
  10. Study sites: 105 to 106v85
  11. Study sites: 104 to 105v84
  12. Study sites: 103 to 104v83
  13. Re-verified, no change to tracked fieldsv82
  14. Site contacts updated at 1 of 103 sitesv81
  15. Study sites: 102 to 103v80
  16. Site contacts updated at 1 of 102 sitesv79
  17. Site contacts updated at 2 of 102 sitesv78
  18. Study sites: 101 to 102v77
  19. Study Status, Outcome Measuresv76
  20. Study sites: 100 to 101v75
  21. Site contacts updated at 1 of 100 sitesv74
  22. Study sites: 98 to 100v73
  23. Study sites: 96 to 98v72
  24. Study sites: 95 to 96v71
  25. Study sites: 94 to 95v70
  26. Site contacts updated at 1 of 94 sitesv69
  27. Study sites: 88 to 94v68
  28. Study Status, Sponsor/Collaboratorsv67
  29. Site contacts updated at 3 of 88 sitesv66
  30. Study sites: 87 to 88v65
  31. Study sites: 86 to 87v64
  32. Study sites: 85 to 86v63
  33. Study sites: 84 to 85v62
  34. Study sites: 78 to 84v61
  35. Site contacts updated at 2 of 78 sitesv60
  36. Study sites: 77 to 78v59
  37. Site contacts updated at 1 of 77 sitesv58
  38. Study sites: 76 to 77v57
  39. Site contacts updated at 2 of 76 sitesv56
  40. Site contacts updated at 1 of 76 sitesv55
  41. Study sites: 72 to 76v54
  42. Study sites: 71 to 72v53
  43. Study sites: 70 to 71v52
  44. Study sites: 68 to 70v51
  45. Site contacts updated at 1 of 68 sitesv50
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Trial Details
NCT Number NCT06072781
Lead Sponsor Verastem, Inc.
Collaborators: GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Conditions Low Grade Serous Ovarian Cancer
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov